Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6)

Clinical Trial ID NCT01720446

Rank	Title	Journal	Year	PubWeight™‹?›
1	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.	N Engl J Med	2016	5.87
2	Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.	Diabetes Metab Syndr Obes	2014	1.05
3	Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.	J Diabetes Complications	2014	0.86
4	The cardiovascular safety of incretin-based therapies: a review of the evidence.	Cardiovasc Diabetol	2013	0.83
5	Current perspectives on cardiovascular outcome trials in diabetes.	Cardiovasc Diabetol	2016	0.79
6	Blood pressure and cardiovascular effects of new and emerging antidiabetic agents.	Curr Hypertens Rep	2014	0.75
7	Cardiovascular effects of anti-diabetes drugs.	Expert Opin Drug Saf	2016	0.75
8	Diabetes Drugs and Cardiovascular Safety.	Endocrinol Metab (Seoul)	2016	0.75
9	Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial.	Herz	2016	0.75
10	Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications.	Clin Pharmacol Ther	2015	0.75